Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Roivant Sciences (ROIV) over the last 4 years, with Mar 2025 value amounting to $6.1 million.

  • Roivant Sciences' Gains from Sales and Divestitures fell 86.62% to $297,795 in Q2 2025 from the same period last year, while for Jun 2025 it was $297,795, marking a year-over-year decrease of 86.62%. This contributed to the annual value of $6.1 million for FY2025, which is 11.03% down from last year.
  • Latest data reveals that Roivant Sciences reported Gains from Sales and Divestitures of $6.1 million as of FY2025, which was up 23.26% from $4.9 million recorded in FY2024.
  • In the past 5 years, Roivant Sciences' Gains from Sales and Divestitures ranged from a high of $12.0 million in FY2023 and a low of $4.9 million during FY2024.
  • Its 3-year average for Gains from Sales and Divestitures is $7.1 million, with a median of $6.1 million in 2025.
  • Data for Roivant Sciences' Gains from Sales and Divestitures shows a maximum YoY plummeted of 42.92% (in 2024) over the last 5 years.
  • Roivant Sciences' Gains from Sales and Divestitures (Yearly) stood at $5.8 million in 2022, then reached $12.0 million in 2023, then dropped by 4.56% to $5.5 million in 2023, then tumbled by 42.92% to $6.8 million in 2024, then decreased by 10.21% to $4.9 million in 2024, then dropped by 11.03% to $6.1 million in 2025.